* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:54:43 ON 09 AUG 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:54:48 ON 09 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file

h eb c g cg b cg eb

provided by InfoChem.

STRUCTURE FILE UPDATES: 7 AUG 2004 HIGHEST RN 723734-66-5
DICTIONARY FILE UPDATES: 7 AUG 2004 HIGHEST RN 723734-66-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR
Ak19N M2



Page 1-A

h eb c g cg b cg eb



Page 1-B
VAR G1=18/19
VPA 14-1/3/4/5/6 S
VPA 15-10/11/12/13 S
NODE ATTRIBUTES:
HCOUNT IS M2 AT 19
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4
NSPEC IS R AT 5
NSPEC IS R AT 6
NSPEC IS C AT 7
NSPEC IS C AT 8
NSPEC IS R AT 9
NSPEC IS R AT 10
NSPEC IS R AT 11
NSPEC IS R AT 12
NSPEC IS R AT 13
NSPEC IS C AT 14
NSPEC IS C AT 15
NSPEC IS C AT 16
NSPEC IS C AT 17
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 7 14 16 17 18 19
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

=> s l1
SAMPLE SEARCH INITIATED 10:57:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1647 TO ITERATE

60.7% PROCESSED 1000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 30506 TO 35374

h eb c g cg b cg eb

```
PROJECTED ANSWERS:                2 TO      173

L2             2 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:57:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  32122 TO ITERATE

100.0% PROCESSED   32122 ITERATIONS                              41 ANSWERS
SEARCH TIME: 00.00.01

L3             41 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   156.68     156.89

FILE 'HCAPLUS' ENTERED AT 10:57:16 ON 09 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 9 Aug 2004  VOL 141 ISS 7
FILE LAST UPDATED: 8 Aug 2004  (20040808/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> s l3
L4             14 L3

=> s l4 and brown, d?/au
          7837 BROWN, D?/AU
L5           2 L4 AND BROWN, D?/AU

=> d l5, ibib abs fhitstr, 1-2

L5   ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

Full Text | Citing References

```
ACCESSION NUMBER:         2001:798214  HCAPLUS
DOCUMENT NUMBER:          135:344368
TITLE:                    Process for the regioselective synthesis of 3,4-diaryl
                          substituted thiophenes
INVENTOR(S):              Brown, David L.; Ludwig, Cindy L.
```

h eb c g cg b cg eb

PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001081333	A2	20011101	WO 2001-US13092		20010420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 2002183362	A1	20021205	US 2001-839424		20010420
EP 1276736	A2	20030122	EP 2001-928781		20010420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
US 6600052	B1	20030729	US 2001-838986		20010420
JP 2003531202	T2	20031021	JP 2001-578424		20010420
US 2003232996	A1	20031218	US 2003-258507		20030416
PRIORITY APPLN. INFO.:			US 2000-199533P	P	20000425
			US 2000-253380P	P	20001127
			WO 2001-US13092	W	20010420

OTHER SOURCE(S): CASREACT 135:344368; MARPAT 135:344368
GI



AB A novel process for the regioselective prepn. of I, via the intermediates II and III using an alkali metal alkoxide ring cyclizing reagent where (R1 and R2 = substituted carbocycle or heterocycle; R3 = OR6 or NR7R8 and R6, R7 and R8 = H, (un)heterosubstituted hydrocarbyl; R4 and R5 are independently H and optionally substituted alkyl), was accomplished. Thus IV was prepd. in 66 % yield via the enamine intermediate of Me 3-[3-fluoro-4-(methylthio)phenyl]-4-phenyl-2-thiophenecarboxylate.

IT **370874-59-2P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 3,4-diarylthiophene)
RN 370874-59-2 HCAPLUS

h eb c g cg b cg eb

CN 2-Thiophenecarboxylic acid, 3-[4-(aminosulfonyl)-3-fluorophenyl]-4-phenyl-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Other References

ACCESSION NUMBER: 2001:798213 HCAPLUS
DOCUMENT NUMBER: 135:344477
TITLE: Preparation of 2-fluorobenzenesulfonyl-heterocycles with COX-1 and COX-2 inhibiting activity for pharmaceutical use in the treatment of inflammation
INVENTOR(S): **Brown, David L.**; Graneto, Matthew J.; Ludwig, Cindy L.; Talley, John J.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 242 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001081332	A2	20011101	WO 2001-US12983		20010420
WO 2001081332	A3	20020404			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 2002183362	A1	20021205	US 2001-839424		20010420
EP 1296971	A2	20030402	EP 2001-927279		20010420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
US 6600052	B1	20030729	US 2001-838986		20010420
JP 2003531201	T2	20031021	JP 2001-578423		20010420
US 2004092552	A1	20040513	US 2003-258493		20030711
PRIORITY APPLN. INFO.:			US 2000-199533P	P	20000425
			US 2000-253380P	P	20001127
			WO 2001-US12983	W	20010420

OTHER SOURCE(S): MARPAT 135:344477
GI

h eb c g cg b cg eb



I



II

AB 2-Fluorobenzenesulfonyl-heterocycles, such as I [A = 5 or 6 membered heterocycle or carbocycle, such as pyrazole, thiophene, isoxazole, furan; R1 = cyclohexyl, pyridinyl, Ph; R2 = Me, NH2; R3 = H, oxo, CN, halogen, alkyl, alkenyl, carboxyl, haloalkyl, heterocyclyl, cycloalkenyl, aminocarbonyl, etc.] with COX-1 and COX-2 inhibiting activity, were prepd. for therapeutic use as anti-inflammatory agents. Thus, pyrazole II was prepd. via a multistep synthetic sequence in which the last step was a a cyclocondensation reaction of 4-H2NSO2-3-F-C6H3NHNH2 and 3-Cl-4-Me-C6H3COCH2COCHF2 achieved by refluxing for 1 h. concd. HCl in EtOH to give II with 53% yield. The prepd. heterocycles were tested for COX-1 and -2 inhibiting activity.

IT **370874-28-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-fluorobenzenesulfonyl-heterocycles with COX-1 and COX-2 inhibiting activity for pharmaceutical use in the treatment of inflammation)

RN 370874-28-5 HCAPLUS

CN Benzenesulfonamide, 2-fluoro-4-(4-phenyl-3-thienyl)- (9CI) (CA INDEX NAME)




```
=> d his

     (FILE 'HOME' ENTERED AT 10:54:43 ON 09 AUG 2004)

     FILE 'REGISTRY' ENTERED AT 10:54:48 ON 09 AUG 2004
L1             STRUCTURE UPLOADED
L2               2 S L1
L3              41 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 10:57:16 ON 09 AUG 2004
L4              14 S L3
L5               2 S L4 AND BROWN, D?/AU

=> s l4 not l5
```

h eb c g cg b cg eb

```
L6          12 L4 NOT L5

=> s l6 and graneto, m?/au
            40 GRANETO, M?/AU
L7           0 L6 AND GRANETO, M?/AU

=> s l6 and ludwig, c?/au
           270 LUDWIG, C?/AU
L8           0 L6 AND LUDWIG, C?/AU

=> d l6, ibib abs fhitstr, 1-12

L6   ANSWER 1 OF 12  HCAPLUS  COPYRIGHT 2004 ACS on STN
```

Full Text | Citing References

ACCESSION NUMBER: 2004:565073 HCAPLUS
TITLE: Use of cathepsin k inhibitors for the treatment of glaucoma
INVENTOR(S): Shepard, Allan; Clark, Abbot F.; Jacobson, Nasreen
PATENT ASSIGNEE(S): Alcon, Inc., Switz.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058238	A1	20040715	WO 2003-US40511	20031219

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-436126P P 20021223

AB Compns. contg. inhibitors of cathepsin K (CTSK) expression and/or activity are provided. Methods for the treatment of glaucoma using the compns. of the invention are further provided. The cathepsin K antagonist is selected from, but not limited to, the group consisting of monensin, brefeldin A, tunicamycin and 1,3-bis(acylamino)-2-propanone derivs., cycloaltilisin 6, cycloaltilisin 7, AC-3-1, AC-3-3, AC-5-1, haploscleridamine, SB-331750, SB-357114, peptidomimetic aminomethyl ketones, α,α'-diacylamino ketones, alkoxymethyl ketones, cyanamides, pyridoxal propionate derivs. (including Clik-164 and Clik-166), SB-290190, α-alkoxy ketone derivs., cyanamide derivs., and Nα-acyl-α-amino acid-(arylaminoethyl)amides.

IT **190658-17-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of cathepsin k inhibitors for treatment of glaucoma)

RN 190658-17-4 HCAPLUS
CN 4-Thiazolecarboxylic acid, 2-[3-[[(4-chlorophenyl)sulfonyl]methyl]-2-

h eb c g cg b cg eb

thienyl]-, 2-[(2S)-4-methyl-1-oxo-2-[[(4-pyridinylmethoxy)carbonyl]amino]p
entyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Other Referencing

ACCESSION NUMBER: 2004:515493 HCAPLUS
DOCUMENT NUMBER: 141:71565
TITLE: Preparation of pyrazines and related compounds as glucokinase activators for the treatment of type II diabetes
INVENTOR(S): Chen, Shaoqing; Corbett, Wendy Lea; Guertin, Kevin Richard; Haynes, Nancy-Ellen; Kester, Robert Francis; Mennona, Francis A.; Mischke, Steven Gregory; Qian, Yimin; Sarabu, Ramakanth; Scott, Nathan Robert; Thakkar, Kshitij Chhabilbhai
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: PCT Int. Appl., 243 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052869	A1	20040624	WO 2003-EP14055	20031211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004147748	A1	20040729	US 2003-732838	20031210
PRIORITY APPLN. INFO.:			US 2002-432806P	P 20021212
			US 2003-524531P	P 20031124

GI

h eb c g cg b cg eb



I

AB Title compd. I [R1 = alkyl; R2 = H, halo, nitro, etc.; R3 = cycloalkyl; R4 = SO2NR5R6, NHSO2CH3, [CH2]mNMe2, etc.; R5 = H, alkyl; R6 = alkyl; Y = CH, N; * denotes an asym. carbon] and their pharmaceutically acceptable salts were prepd. For example, the Pd-catalyzed coupling of 2-amino-5-bromopyrazine with NaSMe, followed by reaction with (2R)-(3-chloro-4-metnanesufonylphenyl)-3-cyclopentylpropionic acid afforded compd. (R)-I [R1 = Me; R2 = Cl; R3 = cyclopetyl; R4 = SMe; Y = N] in 22.1% overall yield. In glucokinase activity assays (in vitro) using glucose-6-phosphate dehydrogenase (G6PDH), compds. I exhibited SC1.5 values less than or equal to 100 μM. Formulations are given. Compds. I are claimed useful for the treatment and prophylaxis of II type diabetes.

IT **710321-98-5P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrazines and related compds. as glucokinase activators for the treatment of type II diabetes)

RN 710321-98-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



L6 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:145039 HCAPLUS

DOCUMENT NUMBER: 136:325469

TITLE: 4-(4-Cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as Selective Cyclooxygenase-2 Inhibitors: Enhancement of the Selectivity by Introduction of a Fluorine Atom and Identification of a Potent, Highly Selective, and

h eb c g cg b cg eb

Orally Active COX-2 Inhibitor JTE-522

AUTHOR(S): Hashimoto, Hiromasa; Imamura, Katsuaki; Haruta, Jun-ichi; Wakitani, Korekiyo

CORPORATE SOURCE: Central Pharmaceutical Research Institute, JT Inc., Takatsuki, Osaka, 569-1125, Japan

SOURCE: Journal of Medicinal Chemistry (2002), 45(7), 1511-1517
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB A series of 4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamide derivs., e.g., I, were synthesized and evaluated for their abilities to inhibit cyclooxygenase-2 (COX-2) and cyclooxygenase-1 (COX-1) enzymes. In this series, substituent effects at the ortho position to the sulfonamide group on the Ph ring were examd. Most substituents reduced or lost both COX-2 and COX-1 activities. In contrast, introduction of a fluorine atom preserved COX-2 potency and notably increased COX1/COX-2 selectivity. This work led to the identification of a potent, highly selective, and orally active COX-2 inhibitor I (JTE-522), which is currently in phase II clin. trials for the treatment of rheumatoid arthritis, osteoarthritis, and acute pain.

IT **415679-14-0P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of substituted benzenesulfonamides as selective cyclooxygenase-2 inhibitors from substituted benzyl bromides via coupling with acid chloride, conversion to α-acetoxy ketones, cyclocondensation to form oxazoles and sulfonamidation)

RN 415679-14-0 HCAPLUS

CN Benzenesulfonamide, 2-fluoro-4-[2-methyl-4-(5-methyl-2-thienyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

h eb c g cg b cg eb

L6 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2002:72091 HCAPLUS
DOCUMENT NUMBER: 136:134566
TITLE: Synthesis and use of heteroaryl-substituted-aryloxyalkylaryl compounds as β3-adrenergic agonists
INVENTOR(S): Evers, Britta; Jesudason, Cynthia Darshini; Karanjawala, Rushad Eruch; Remick, David Michael; Ruehter, Gerd; Sall, Daniel Jon; Schotten, Theo; Siegel, Miles Goodman; Stenzel, Wolfgang; Stucky, Russell Dean; Werner, John Arnold
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002006276	A1	20020124	WO 2001-US16519		20010709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 2001072917	A5	20020130	AU 2001-72917		20010709
EP 1303509	A1	20030423	EP 2001-952125		20010709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001012409	A	20030722	BR 2001-12409		20010709
JP 2004504320	T2	20040212	JP 2002-512179		20010709
US 2003191156	A1	20031009	US 2002-311112		20021213
US 6730792	B2	20040504			
NO 2003000098	A	20030109	NO 2003-98		20030109
HR 2003000018	A1	20030430	HR 2003-18		20030113
PRIORITY APPLN. INFO.:			US 2000-217965P	P	20000713
			US 2000-241614P	P	20001019
			US 2001-292988P	P	20010523
			WO 2001-US16519	W	20010709

OTHER SOURCE(S): MARPAT 136:134566
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A1-3 = C, N provided that only one of A1-3 can be nitrogen; Het = (un)substituted, optionally benzofused 5 or 6 membered heterocyclic ring; R1,1a,1b = H, halo, OH, alkyl, alkoxy, haloalkyl, SO2-alkyl; R2 = H, alkyl; R3 = H alkyl; R4 = H, alkyl; or R3 and R4

h eb c g cg b cg eb

combine with the carbon to which both are attached to form a C3-C6 cyclic ring; or R4 and X1 combine with the carbon to which both are attached to form a C3-C8 cyclic ring; or R4 combines with X1, the carbon to which both are attached, and the Ph group to which X1 is attached to form a benzofused cycloalkyl radical; X is OCH2, SCH2, bond; X1 = bond, divalent hydrocarbon moiety; X2 = O, S, NH, NHSO2, SO2NH, CH2, bond; X3 = (un)substituted Ph, 5 or 6 membered heterocyclic ring] were prepd. For instance, 2-(1-methylpyrazol-3-yl)phenol was reacted with (2S)-glycidyl 3-nitrobenzenesulfonate (THF, t-BuOK, reflux, 16 h) to give epoxide II. This was reacted with the amine derived from 4-(2-amino-2-methylpropyl)phenol and 2-chloro-3-cyanopyridine (alc. solvent, 80°C, 2-72 h) to give III. The intrinsic activity (Emax) of representative compds. of the invention was assessed relative to isoproterenol (a nonselective β3-agonist); III had Emax = 55.0%. I are used in the treatment of diabetes, obesity, etc.

IT **391922-26-2P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; synthesis and use of heteroaryl-substituted-aryloxyalkylaryl compds. as β3-adrenergic agonists)

RN 391922-26-2 HCAPLUS

CN 2-Propanol, 1-[[2-[4-[2-chloro-4-(methylsulfonyl)phenoxy]phenyl]-1,1-dimethylethyl]amino]-3-[2-(2-thienyl)phenoxy]-, (2S)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 391922-25-1
CMF C30 H32 Cl N O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS

h eb c g cg b cg eb

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | More References

ACCESSION NUMBER: 2000:637744 HCAPLUS
DOCUMENT NUMBER: 134:39080
TITLE: A method for including protein flexibility in protein-ligand docking: improving tools for database mining and virtual screening
AUTHOR(S): Broughton, H. B.
CORPORATE SOURCE: Merck, Sharp & Dohme Neuroscience Research Centre, Essex, UK
SOURCE: Journal of Molecular Graphics & Modelling (2000), 18(3), 247-257
CODEN: JMGMFI; ISSN: 1093-3263
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Second-generation methods for docking ligands into their biol. receptors, such as FLOG, provide for flexibility of the ligand but not of the receptor. Mol. dynamics based methods, such as free energy perturbation, account for flexibility, solvent effects, etc., but are very time consuming. We combined the use of statistical anal. of conformational samples from short-run protein mol. dynamics with grid-based docking protocols and demonstrated improved performance in two test cases. Our statistical anal. explores the importance of the av. strength of a potential interaction with the biol. target and optionally applies a weighting depending on the variability in the strength of the interaction seen during dynamics simulation. Using these methods, we improved the no. of known dihydrofolate reductase ligands found in the top-ranked 10% of a database of drug-like mols., in searches based on the three-dimensional structure of the protein. These methods are able to match the ability of manual docking to assess likely inactivity on steric grounds and indeed to rank order ligands from a homologous series of cyclooxygenase-2 inhibitors with good correlation to their true activity. Furthermore, these methods reduce the need for human intervention in setting up mol. docking expts.

IT **312611-71-5**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(method for including protein flexibility in protein-ligand docking - improving tools for database mining and virtual screening)

RN 312611-71-5 HCAPLUS
CN Thiophene, 3-[3-bromo-4-(methylsulfonyl)phenyl]-4-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

h eb c g cg b cg eb

L6 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:795808 HCAPLUS
DOCUMENT NUMBER: 132:35714
TITLE: Preparation of heterocyclyl sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
INVENTOR(S): Ando, Kazuo; Kato, Tomoki; Kawai, Akiyoshi; Nonomura, Tomomi
PATENT ASSIGNEE(S): Pfizer Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 236 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964415	A1	19991216	WO 1999-IB970	19990531
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9938414	A1	19991230	AU 1999-38414	19990531
EP 1086097	A1	20010328	EP 1999-921043	19990531
EP 1086097	B1	20040519		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002517496	T2	20020618	JP 2000-553424	19990531
AT 267196	E	20040615	AT 1999-921043	19990531
ZA 9903897	A	20010104	ZA 1999-3897	19990610
US 6294558	B1	20010925	US 1999-446049	19991215
US 2002045654	A1	20020418	US 2001-841348	20010424
US 6608095	B2	20030819		
US 2003225064	A1	20031204	US 2003-465767	20030618
US 6727238	B2	20040427		

PRIORITY APPLN. INFO.:

WO 1998-IB912	W	19980611
WO 1999-IB970	W	19990531
US 1999-446049	A3	19991215
US 2001-841348	A3	20010424

OTHER SOURCE(S): MARPAT 132:35714
GI

h eb c g cg b cg eb



I



II

AB This invention provides a compd. of formula (I) or its pharmaceutically acceptable salt thereof [wherein A is partially unsatd. or unsatd. five membered heterocyclic, or partially unsatd. or unsatd. five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted Ph in formula I are attached to ring atoms of Ring A, which are adjacent to each other; R1 is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R1 is heteroaryl; R2 is C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkylamino, C1-4 dialkylamino or amino; R3, R4 and R5 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl or the like; or two of R3, R4 and R5 are taken together with atoms to which they are attached and form a 4-7 membered ring; R6 and R7 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino or N,N-di C1-4 alkylamino; and m and n are independently 1, 2, 3 or 4]. This invention also provides a pharmaceutical compn. useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens. This invention relates to compd. and pharmaceutical compns. for the treatment of cyclooxygenase mediated diseases. These compds. inhibit the biosynthesis of prostaglandins by intervention of the action of the enzyme cyclooxygenase on arachidonic acid, and are therefore useful in the treatment or alleviation of inflammation and other inflammation assocd. disorders, such as arthritis, in mammals (no data). Thus, To a stirred soln. of 1-[4-(Methylsulfonyl)phenyl]-5-(4-bromophenyl)-3-trifluoromethyl-1H-pyrazole (0.27 g) in DME (8 mL) was added 3-thiophenboronic acid (0.09 g), bis(triphenylphosphine)palladium(II)chlor ide (0.05 g) and satd. NaHCO3 soln. (2 mL) at room temp. under nitrogen. The mixt. was heated at reflux temp. for 16 h, and cooled down to room temp. to give, after purifn. by flash chromatog. eluting with Et acetate/hexane (1/1), 1-[4-(Methylsulfonyl)phenyl]-5-[4-(2-thienyl)phenyl]-3-trifluoromethyl-1H-pyrazole (II) in 64 % yield.

IT **252559-81-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclyl sulfonylbenzene compds. as cyclooxygenase inhibitors, prostaglandin biosynthesis inhibitors, anti-inflammatory, and analgesic agents)

RN 252559-81-2 HCAPLUS

CN 1H-Pyrazole, 1-[3-fluoro-4-(methylsulfonyl)phenyl]-5-[4-(2-thienyl)phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

h eb c g cg b cg eb



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Hits to References

ACCESSION NUMBER: 1999:82258 HCAPLUS
DOCUMENT NUMBER: 130:210722
TITLE: Synthesis and properties of novel aziridinyl azo dyes from 2-aminothiophenes-Part 2: Application of some disperse dyes to polyester fibers
AUTHOR(S): Hallas, Geoffrey; Choi, Jae-Hong
CORPORATE SOURCE: Dep. Colour Chemistry and Dyeing, Univ. Leeds, Leeds, LS2 9JT, UK
SOURCE: Dyes and Pigments (1998), Volume Date 1999, 40(2-3), 119-129
CODEN: DYPIDX; ISSN: 0143-7208
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of yellow to greenish-blue aziridinyl azo dyes and their bromoethylamino azo precursors contg. a thienyl coupling moiety has been applied to conventional polyester fiber as well as microdenier polyester by high temp. exhaust dyeing. Heat transferability of these dyes onto polyester fiber has also been examd., using conventional heat-transfer printing techniques. The relevant dyeing characteristics, heat transferability, build-up, dyeability on microfiber polyester, washfastness, and lightfastness are given. These aziridinyl dyes are reactive to polyester fibers under HT dyeing conditions. Fabrics dyed with aziridinyl dyes re more resistant to solvent extn. than those dyed with conventional dyes. Residual liquors showed only a pale color when fabric dyed with aziridinyl dyes was dissolved and then pptd., whereas a colored polyester ppt. was obtained.

IT **220964-99-8**
RL: PRP (Properties); TEM (Technical or engineered material use); USES (Uses)
(brown dye; fastness to polyester under high-temp. exhaust dyeing and thermal-transfer printing conditions)

RN 220964-99-8 HCAPLUS
CN 3-Thiophenecarboxylic acid, 2-[(2-bromoethyl)amino]-5-[[2-chloro-4-(methylsulfonyl)phenyl]azo]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

h eb c g cg b cg eb



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1999:82257 HCAPLUS
DOCUMENT NUMBER: 130:210776
TITLE: Synthesis and properties of novel aziridinyl azo dyes from 2-aminothiophenes-Part 1: Synthesis and spectral properties
AUTHOR(S): Hallas, Geoffrey; Choi, Jae-Hong
CORPORATE SOURCE: Department Colour Chemistry and Dyeing, Univ. Leeds, Leeds, LS2 9JT, UK
SOURCE: Dyes and Pigments (1998), Volume Date 1999, 40(2-3), 99-117
CODEN: DYPIDX; ISSN: 0143-7208
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of yellow to greenish-blue aziridinyl azo dyes and their bromoethylamino azo precursors contg. a thienyl coupling moiety has been prepd. from 2-aminothiophenes. The 2-aminothiophenes were readily obtained by using the Gewald reaction. It was found that cyclization of the precursor dyes to the corresponding aziridine azo dyes brought about bathochromic shifts in absorption maxima. Further spectral comparisons with N-Ph azo dyes derived from other terminal 4-, 5-, 6-, 7-, and 8-membered cyclic groups showed that the N-thienylaziridinoazo dyes are relatively bathochromic. From the viewpoint of solvatochromism, a clear contrast existed between λmax values in different solvents; thus, a pos. solvatochromism was obsd. in aprotic solvents, whereas a hypsochromic shift was brought about in polar protic solvents. PPP-MO calcns. provided reliable predictions of absorption maxima for the various aziridinyl azo dyes and their precursor dyes.

IT **220964-99-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(brown dye intermediate; prepn. of aziridinyl azo dyes from 2-aminothiophene coupling components)

RN 220964-99-8 HCAPLUS
CN 3-Thiophenecarboxylic acid, 2-[(2-bromoethyl)amino]-5-[[2-chloro-4-(methylsulfonyl)phenyl]azo]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

h eb c g cg b cg eb



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Other References

ACCESSION NUMBER: 1997:421308 HCAPLUS
DOCUMENT NUMBER: 127:34521
TITLE: Preparation of hydrazidyl, bis-hydrazidyl, and bis-aminomethyl carbonyl protease inhibitors
INVENTOR(S): Carr, Thomas Joseph; Desjarlais, Renee Louise; Gallagher, Timothy Francis; Halbert, Stacie Marie; Oh, Hye-Ja; Thompson, Scott Kevin; Veber, Daniel Frank; Yamashita, Dennis Shinji; et al.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 253 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9716433	A1	19970509	WO 1996-US18000	19961030
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, US, US, US, US, US, US, US, US, US, US, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9609078	A	19980429	ZA 1996-9078	19961029
CA 2236111	AA	19970509	CA 1996-2236111	19961030
AU 9711180	A1	19970522	AU 1997-11180	19961030
CN 1207095	A	19990203	CN 1996-199284	19961030
BR 9612344	A	19990713	BR 1996-12344	19961030
EP 934291	A1	19990811	EP 1996-941981	19961030
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
NO 9801938	A	19980629	NO 1998-1938	19980429
US 5998470	A	19991207	US 1999-290958	19990413
US 6057362	A	20000502	US 1999-330287	19990611
US 6232342	B1	20010515	US 1999-330451	19990611
US 6284777	B1	20010904	US 2000-552616	20000419
US 6331542	B1	20011218	US 2000-551968	20000419
NO 2000006716	A	19980629	NO 2000-6716	20001229
NO 2000006717	A	19980629	NO 2000-6717	20001229
NO 2000006718	A	19980629	NO 2000-6718	20001229
CN 1341590	A	20020327	CN 2001-104787	20010220
CN 1341592	A	20020327	CN 2001-104788	20010220

h eb c g cg b cg eb

CN 1341593	A	20020327	CN 2001-104789		20010220
US 2002077455	A1	20020620	US 2001-839410		20010420
US 6586466	B2	20030701			
US 2002173469	A1	20021121	US 2002-160314		20020530
US 6562842	B2	20030513			
PRIORITY APPLN. INFO.:			US 1995-8108P	P	19951030
			US 1995-7473P	P	19951122
			US 1995-8992P	P	19951221
			US 1996-13747P	P	19960320
			US 1996-13748P	P	19960320
			US 1996-13764P	P	19960320
			US 1996-17455P	P	19960517
			US 1996-17892P	P	19960517
			US 1996-22047P	P	19960722
			US 1996-23494P	P	19960807
			WO 1996-US18000	W	19961030
			US 1997-793915	A3	19970214
			US 1998-793915	B3	19980430
			US 1999-330284	B1	19990611
			US 1999-330305	B1	19990611
			US 2000-633700	B1	20000807

OTHER SOURCE(S): MARPAT 127:34521

AB Title compds. of formula D-CO-Q [D = CbzNHCH(Bu-i), Cbz-Leu-NHCH(Bu-i), 4-PhOC6H4SO2NHCH2, Cbz-Leu-NHNH, etc.; Q = NHCH(Bu-i)(2-carboxythiazol-4-yl), NHCH(Bu-i)(4-carboethoxythiazol-2-yl), NHNHCOCH(Bu-i)NHCbz, CH2NHSO2C6H4-4-OPh, etc.; Cbz = PhCH2O2C] and pharmaceutical compns. of such compds., which inhibit proteases, including cathepsin K (no data) were prepd. Such compds. are particularly useful for treating diseases of excessive bone loss or cartilage or matrix degrdn., e.g. osteoporosis, periodontitis, and arthritis. For example, Cbz-Leu-Leu-CH2Br was treated with H2NCSCO2Et in refluxing ethanol for 4 h to give Cbz-Leu-NHCH(Bu-i)(2-carboethoxythiazol-4-yl), which was sapond. by treatment with sodium hydroxide in THF to yield title compd. Cbz-Leu-NHCH(Bu-i)(2-carboxythiazol-4-yl).

IT **190658-17-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hydrazidyl, bis-hydrazidyl, and bis-aminomethyl carbonyl protease inhibitors)

RN 190658-17-4 HCAPLUS

CN 4-Thiazolecarboxylic acid, 2-[3-[[(4-chlorophenyl)sulfonyl]methyl]-2-thienyl]-, 2-[(2S)-4-methyl-1-oxo-2-[[(4-pyridinylmethoxy)carbonyl]amino]pentyl]hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

h eb c g cg b cg eb

Full Text | Citing References

ACCESSION NUMBER: 1995:339482 HCAPLUS
DOCUMENT NUMBER: 122:105655
TITLE: Preparation of 2-substituted-3,4-di(aryl)thiophene cyclooxygenase inhibitors
INVENTOR(S): Gauthier, Jacques Yves; Leblanc, Yves; Prasit, Petpiboon
PATENT ASSIGNEE(S): Merck Frosst Canada Inc., Can.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9426731	A1	19941124	WO 1994-CA264		19940511
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TT, UA, US, UZ					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
CA 2161789	AA	19941124	CA 1994-2161789		19940511
AU 9467184	A1	19941212	AU 1994-67184		19940511
PRIORITY APPLN. INFO.:			US 1993-61354	A	19930513
			WO 1994-CA264	W	19940511

OTHER SOURCE(S): MARPAT 122:105655
GI



I

AB The title compds. [I; R1 = H, halogen, CN, NO2, CF3, C1-6 alkyl; R2 = C3-6 alkyl, (un)substituted Ph, (un)substituted heteroaryl; R3 = SO2CH3, S(O)(NH)CH3, SONH2, SO2NH2; R4 = H, halogen, CO2H, CF3], useful as cyclooxygenase inhibitors, are prepd. and I-contg. formulations claimed. Thus, 3-(4-fluorophenyl)-4-(4-sulfamoylphenyl)thiophene was prepd. and demonstrated 95% inhibition of PGE2 formation by osteosarcoma (143.98.2) cells at 100 nM.

IT **160753-08-2**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of 2-substituted-3,4-di(aryl)thiophene cyclooxygenase inhibitors)
RN 160753-08-2 HCAPLUS
CN Thiophene, 3-[3-bromo-4-(methylsulfonyl)phenyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

h eb c g cg b cg eb



L6 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 1987:5016 HCAPLUS
DOCUMENT NUMBER: 106:5016
TITLE: Thiazolylthiophene derivatives
INVENTOR(S): Saeki, Sumi; Kawakita, Takeshi; Moriguchi, Akihiko; Osuga, Kunio
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61118383	A2	19860605	JP 1984-237865	19841112
PRIORITY APPLN. INFO.:			JP 1984-237865	19841112

OTHER SOURCE(S): CASREACT 106:5016
GI



AB The title compds. [I; R = Q; R1 = (substituted) amino; R2 = alkanoyl, CH2COR3 (R3 = OH, alkoxy, substituted amino), X = H, halo], useful as antiulcer agents, etc. (no data), were prepd. Thus, cyclocondensation of Q1COCH2Cl with (H2N)2CS in EtOH at 50° and acylation of the resulting I (R = Q1; R1 = NH2) with pivaloyl chloride in pyridine gave I (R = Q1; R1 = pivalamido).

IT **105652-30-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antiulcer agent)

RN 105652-30-0 HCAPLUS
CN Benzamide, N-[4-(5-acetyl-3-thienyl)-2-thiazolyl]-3-(aminosulfonyl)-4-chloro- (9CI) (CA INDEX NAME)

h eb c g cg b cg eb



L6 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text | Related References

ACCESSION NUMBER: 1983:145034 HCAPLUS
DOCUMENT NUMBER: 98:145034
TITLE: Thienylthiazole disazo disperse dyes
PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 57177060	A2	19821030	JP 1981-62070	19810424
JP 01034266	B4	19890718		
GB 2101623	A	19830119	GB 1982-11221	19820419
GB 2101623	B2	19840822		
DE 3215123	A1	19821209	DE 1982-3215123	19820423
DE 3215123	C2	19900308		
CH 647537	A	19850131	CH 1982-2539	19820426
US 4841036	A	19890620	US 1984-683323	19841218
PRIORITY APPLN. INFO.:			JP 1981-62070	19810424
			US 1982-372264	19820426

GI



AB I (R = Ph, pyridyl, thiazolyl; R1 = H, Cl, Br, Ac; R2 = H, Cl, Br, Me, acylamino; R3 = H, Cl, Me, MeO, EtO; R4, R5 = H, alkyl, cyclohexyl, alkenyl, aryl) were prepd. and were used for dyeing polyester fibers in fast navy blue to green shades. I showed excellent stability to temp. and pH changes during dyeing. For example, aniline [62-53-3] was diazotized and coupled with 2-amino-4-(2-thienyl)thiazole [28989-50-6], and the 2-amino-5-(phenylazo)-4-(2-thienyl)thiazole [85242-87-1] obtained was diazotized and coupled with N-(2-acetoxyethyl)-N-ethylaniline [38954-40-4] to give I (R = Ph; R1 = R2 = R3 = H; R4 = Et; R5 = CH2CH2OAc) [85242-88-2], navy blue on polyester fiber.

IT **85242-65-5**
RL: TEM (Technical or engineered material use); USES (Uses)
(dye, for polyester fibers)

RN 85242-65-5 HCAPLUS

h eb c g cg b cg eb

CN Propanenitrile, 3-[[4-[[5-[[2-chloro-4-(methylsulfonyl)phenyl]azo]-4-(2-thienyl)-2-thiazolyl]azo]phenyl]ethylamino]- (9CI) (CA INDEX NAME)



=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	74.92	231.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.29	-10.29

FILE 'CAOLD' ENTERED AT 10:58:25 ON 09 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 10:54:43 ON 09 AUG 2004)

FILE 'REGISTRY' ENTERED AT 10:54:48 ON 09 AUG 2004
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 41 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 10:57:16 ON 09 AUG 2004
L4 14 S L3
L5 2 S L4 AND BROWN, D?/AU

h eb c g cg b cg eb

```
L6             12 S L4 NOT L5
L7              0 S L6 AND GRANETO, M?/AU
L8              0 S L6 AND LUDWIG, C?/AU

     FILE 'CAOLD' ENTERED AT 10:58:25 ON 09 AUG 2004

=> s l3
L9              0 L3

=>
```

h eb c g cg b cg eb